Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Demetrio Hechanova

Cardiovascular Disease Covina, CA Medical Doctor

NPI 1275584203 CMS profile 193526

315 N 3Rd Ave, Suite 207, Covina, CA 91723

Open in the dashboard

General payments

$12,472

707 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Demetrio Hechanova of Covina, CA is reported in the CMS Open Payments database as having received $12,472 across 707 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,075 55
2024 General $1,573 75
2023 General $1,826 96
2022 General $2,173 124
2021 General $2,145 138
2020 General $1,384 86
2019 General $2,297 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Demetrio Hechanova
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Demetrio Hechanova were reported at $1,075. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Demetrio Hechanova Cardiovascular Disease median Middle half National median
2019 $2,297 $450 $127–$1,392 $163
2020 $1,384 $242 $77–$751 $114
2021 $2,145 $335 $101–$1,037 $132
2022 $2,173 $395 $121–$1,211 $149
2023 $1,826 $443 $136–$1,283 $160
2024 $1,573 $450 $136–$1,323 $164
2025 $1,075 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,950 170 payments
  2. Pfizer Inc. $1,361 76 payments
  3. Janssen Pharmaceuticals, Inc $1,009 54 payments
  4. AstraZeneca Pharmaceuticals LP $893 46 payments
  5. Merck Sharp & Dohme Corporation $780 40 payments
  6. Abbott Laboratories $770 26 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $745 35 payments
  8. Boston Scientific Corporation $651 34 payments
  9. Amgen Inc. $641 34 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $507 42 payments
  11. Other $3,165 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,447 705 payments
  2. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. ENTRESTO $1,153 102 payments
  2. XARELTO $1,009 54 payments
  3. ELIQUIS $994 56 payments
  4. VERQUVO $901 46 payments
  5. FARXIGA $726 36 payments
  6. JARDIANCE $672 31 payments
  7. Repatha $618 33 payments
  8. LEQVIO $586 47 payments
  9. LifeVest $507 42 payments
  10. VYNDAQEL $367 20 payments
  11. Other $6,355 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

3,834

Median for Cardiology: 2,533

Drug cost

$1,062,548

Median for Cardiology: $485,213

Branded share of claims

32.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 390 $429,942
Xarelto Rivaroxaban Brand 204 $239,021
Entresto Sacubitril/Valsartan Brand 134 $178,848
Farxiga Dapagliflozin Propanediol Brand 66 $58,898
Brilinta Ticagrelor Brand 36 $35,047
Repatha Sureclick Evolocumab Brand 26 $23,938
Inpefa Sotagliflozin Brand 18 $17,415
Livalo Pitavastatin Calcium Brand 27 $16,583
Jardiance Empagliflozin Brand 11 $16,262
Metoprolol Succinate Generic 323 $4,772

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$152,517

Medicare's payments for the services billed

Medicare patients

602

Average age 77

Services billed

2,352

315 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 57%
Arthritis 51%
Ischemic heart disease 49%
Chronic kidney disease 46%
Heart failure 44%
Atrial fibrillation 40%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $242
$242 204 —
ELIQUIS
  • PFIZER INC. $150
$150 390 —
VERQUVO
  • Merck Sharp & Dohme Corporation $120
$120 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $118
$118 18 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $114
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

707 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record